title: Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
abstract: Between July 2003 and March 2004, nine patients with pretreated mycosis fungoides were enrolled into a phase II trial and were treated with temozolomide. The overall response rate was 33%. Further studies are needed to test the efficacy of temozolomide, alone or in combination in earlier stages of this disease.
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Mariapaola
authors.initials: M
authors.lastname: Fina
authors.forename: Lapo
authors.initials: L
authors.lastname: Alinari
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000368:Aged; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D000077204:Temozolomide
chemical_list: D003606:Dacarbazine; D000077204:Temozolomide